EGFR and colorectal carcinoma: For example, small molecules or monoclonal antibodies targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and BRAF have a positive effect on improving the survival rate and quality of life for CRC patients.4